<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05048615</url>
  </required_header>
  <id_info>
    <org_study_id>HE21-00014</org_study_id>
    <nct_id>NCT05048615</nct_id>
  </id_info>
  <brief_title>Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML</brief_title>
  <official_title>Efficacy and Safety of Ambulatory Low-dose Venetoclax and Azacitidne as First Line Therapy in Newly Diagnosed AML: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Dr. Jose E. Gonzalez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Dr. Jose E. Gonzalez</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Venetoclax plus azacitidine are effective in treating newly diagnosed AML in patients who&#xD;
      cannot recieve intensive chemotherapy. However there is no clinical data rewarding the&#xD;
      efficacy and safety of low-dose venetoclax and azacitidine as first-line therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Venetoclax plus azacitidine are effective in treating newly diagnosed AML in patients who&#xD;
      cannot recieve intensive chemotherapy. However there is no clinical data rewarding the&#xD;
      efficacy and safety of low-dose venetoclax and azacitidine as first-line therapy. This phase&#xD;
      2 clinical trial will explore the efficacy and safety of low-dose venetoclax (100mg /day/21&#xD;
      days) and a fixed dose of azacitidine (75mg/m2, maximun dose 100mg, SC for seven consecutive&#xD;
      days) for a maximun of two cycles.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 26, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A consecutive sample of 15 patients with newly diagnosed AML will be prospectively included in this study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This is an Open label study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility will be address by obtaining the proportion of patients who need hospitalization</measure>
    <time_frame>1 month</time_frame>
    <description>If therapy is feasible &gt;50% of patients will recieve their first cycle of treatment without hospitalization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety will be defined by the number of patients deceased before 14 days of initiating treatment</measure>
    <time_frame>2 weeks</time_frame>
    <description>If therapy is safe then &lt;5% of patients will die in the first 14 days of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy will be achieved if the overall response rate is similar to standard of care (7+3)</measure>
    <time_frame>2 months</time_frame>
    <description>If the therapy is effective then overall response rates will be similar to those reported with standard of care (7+3)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>AML</condition>
  <arm_group>
    <arm_group_label>Low-dose Ventoclax and oral itraconazol plus subcutaneous Azacitdine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will recieve Low-dose Venetoclax at a dose of 100mg/day por 21 days, oral itraconazol 100mg every 12 hours, and subcutaneous Azacitidine 75mg/m2 (maximun dose 100mg) daily for seven days. Each cycle duration is 21 days and patients will recieve a maximun of two cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax 100 MG</intervention_name>
    <description>Patients will receive oral Venetoclax at a fixed dose of 100mg/day from day 1 to day 21 per cycle for a maximum of 2 cycles.</description>
    <arm_group_label>Low-dose Ventoclax and oral itraconazol plus subcutaneous Azacitdine</arm_group_label>
    <other_name>Venclexta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole capsule</intervention_name>
    <description>Patients will receive oral itraconazole at a dose of 100 mg every 12 hours from day 1 to day 21.</description>
    <arm_group_label>Low-dose Ventoclax and oral itraconazol plus subcutaneous Azacitdine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine Injection</intervention_name>
    <description>Patients will receive a maximum of two cycles of daily subcutaneous Azacitidine at a dose of 75 mg/m2 (maximum 100 mg) from day 1 to day 7.</description>
    <arm_group_label>Low-dose Ventoclax and oral itraconazol plus subcutaneous Azacitdine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;18 years&#xD;
&#xD;
          2. Both genders&#xD;
&#xD;
          3. Diagnosis of non-m3 AML by the WHO 2016 diagnostic criteria&#xD;
&#xD;
          4. Patients eligible and not eligible for transplant&#xD;
&#xD;
          5. AML secondary to treatment or associated to myelodisplasia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. AML with PML/RAR-alfa translocation t(15;17)&#xD;
&#xD;
          2. Central nervous system involvement&#xD;
&#xD;
          3. Poor functional status (ECOG&gt;2)&#xD;
&#xD;
          4. Organic dysfunction (Marshall score ≥2)&#xD;
&#xD;
          5. Active infection&#xD;
&#xD;
          6. Use of other CYP3A4 inhibitors&#xD;
&#xD;
          7. Pregnancy&#xD;
&#xD;
          8. GFR &lt;30 ml/min/1.72m2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Gomez-Almaguer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Autonoma de Nuevo Leon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andres Gomez</last_name>
    <phone>818470002</phone>
    <email>drgomezdeleon@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Perla Colunga</last_name>
    <phone>818470002</phone>
    <email>colunga.perla@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Andres Gomez</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo LEON</state>
        <zip>64710</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andres Gomez</last_name>
      <phone>818470002</phone>
      <email>drgomezdeleon@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015 Sep 17;373(12):1136-52. doi: 10.1056/NEJMra1406184. Review.</citation>
    <PMID>26376137</PMID>
  </reference>
  <reference>
    <citation>Guerra VA, DiNardo C, Konopleva M. Venetoclax-based therapies for acute myeloid leukemia. Best Pract Res Clin Haematol. 2019 Jun;32(2):145-153. doi: 10.1016/j.beha.2019.05.008. Epub 2019 May 24. Review.</citation>
    <PMID>31203996</PMID>
  </reference>
  <reference>
    <citation>Pollyea DA, Amaya M, Strati P, Konopleva MY. Venetoclax for AML: changing the treatment paradigm. Blood Adv. 2019 Dec 23;3(24):4326-4335. doi: 10.1182/bloodadvances.2019000937. Erratum in: Blood Adv. 2020 Mar 24;4(6):1020.</citation>
    <PMID>31869416</PMID>
  </reference>
  <reference>
    <citation>DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, Xu T, Hong WJ, Chyla B, Potluri J, Pollyea DA, Letai A. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019 Jan 3;133(1):7-17. doi: 10.1182/blood-2018-08-868752. Epub 2018 Oct 25.</citation>
    <PMID>30361262</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 26, 2021</study_first_submitted>
  <study_first_submitted_qc>September 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Dr. Jose E. Gonzalez</investigator_affiliation>
    <investigator_full_name>David Gomez Almaguer</investigator_full_name>
    <investigator_title>Head of Hematology Service</investigator_title>
  </responsible_party>
  <keyword>acute myeloid leukemia</keyword>
  <keyword>venetoclax</keyword>
  <keyword>azacitidine</keyword>
  <keyword>first-line therapy</keyword>
  <keyword>induction chemotherapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

